← Eichor
Study identifier: NCT07042802 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

Condition: Ovarian Cancer  ·  Sponsor: Nanjing Leads Biolabs Co.,Ltd

PhasePhase 1/Phase 2
Planned participants110
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This trial is an open-label, multicenter phase Ib/II clinical study of LBL-024 combination therapy in patients with platinum-resistant ovarian cancer (OC),To evaluate the efficacy and safety of LBL-024 combination therapy in the treatment of advanced recurrent platinum-resistant ovarian cancer (OC) patients.

This description comes directly from the study's public registry record.

Talk to the study team

lingying wu  ·  025-83378099  ·  mengdongtao@leadsbiolabs.com

Always discuss trial participation with your own doctor first.

Locations (13)

Cancer Institute and Hospital, Chinese Academy of Medical SciencesBeijing, Beijing Municipality, ChinaRecruiting
Beijing Obstetrics and Gynecology Hospital Capital Medical UniversityBeijing, Beijing Municipality, ChinaNot Yet Recruiting
Fujian Cancer HospitalFuzhou, Fujian, ChinaNot Yet Recruiting
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, ChinaNot Yet Recruiting
Harbin Medical University Cancer HospitalHarbin, Heilongjiang, ChinaNot Yet Recruiting
AnYang Tumor HospitalAnyang, Henan, ChinaRecruiting
The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, Henan, ChinaNot Yet Recruiting
The Affiliated Hospital of Xuzhou Medical UniversityXuzhou, Jiangsu, ChinaRecruiting
The First Hospital of China Medical UniversityShenyang, Liaoning, ChinaRecruiting
Shandong Cancer HospitalJinan, Shandong, ChinaRecruiting
Tianjin Medical University Cancer Institute &HospitalTianjin, Tianjin Municipality, ChinaRecruiting
Yunnan Cancer HospitalKunming, Yunnan, ChinaRecruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07042802